Pharmacotherapy of essential thrombocythemia

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1679-1685

  Gangat, Naseema ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aspirin; Essential thrombocythemia; Hydroxycarbamide; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; PHOSPHORUS; PIPOBROMAN;

ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; BODY TEMPERATURE; BONE MARROW TOXICITY; CARDIOMEGALY; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPLETE HEART BLOCK; CONGESTIVE HEART FAILURE; CONSTIPATION; CONVULSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM ULCER; FATIGUE; FLU LIKE SYNDROME; HAIR LOSS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INJECTION SITE ERYTHEMA; INJECTION SITE HARDNESS; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEG ULCER; LEUKEMIA; LOW DRUG DOSE; LUNG FIBROSIS; LUNG INFILTRATE; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; MYELOFIBROSIS; NAUSEA; OVERALL SURVIVAL; PANCREATITIS; PERICARDITIS; POLYCYTHEMIA VERA; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; SKIN PIGMENTATION; STOMACH ULCER; STOMATITIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREA NITROGEN BLOOD LEVEL; VON WILLEBRAND DISEASE; WEAKNESS;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPIRIN; DISEASE PROGRESSION; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 48049083063     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1679     Document Type: Review

References (51)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110(4):1092-7
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14-22
3. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117(10):755-61
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434(7037):1144-8
5. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005;19(10):1847-9
6. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005;131(2):208-13
7. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128(3):275-90
8. Rozman C, Giralt M, Feliu F, et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67(10):2658-63
9. Wolanskyj AP, Schwager SM, Mcclure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81(2):159-66
10. Cortelazzo S, Finnazi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332(17):1132-6
11. Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998;103(3):772-7
12. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8(3):556-62
13. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109(6):2310-3
14. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13(2):150-4
15. Watson KV, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors. Br J Haematol 1993;83(2):198-203
16. Gangat N, Wolanskyj AP, Schwager SM, et al. Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia. Cancer 2006;106(11):2406-11
17. Van Genderen PJ, Prins FJ, Lucas IS, et al. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 1997;99(4):832-6
18. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 2006;108(7):2493-4
19. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96(13):4261-6
20. Jensen MK, De Nully Brown P, Lund BV, et al. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66(3):143-51
21. Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109(11):2279-84
22. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic: syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91(2):616-22
23. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007;21(2):270-6
24. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85(3):124-7
25. Furgerson JL, Vukelja SJ, Baker VJ, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 1996;51(2):137-40
26. Liozon E, Brigaudeau C, Trimoreau F, et al. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997;39(1):11-8
27. Lofvenberg E, Nordenson I, Wahlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet 1990;49(1):57-67
28. Ferrari D, Ticozzelli G, De Vizzi M, et al. Essential thrombocythemia and acute leukemia. Haematologica 1993;78(6):401-2
29. Griesshammer M. Risk Ectors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 2006;32(4 Part 2):372-80
30. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97(4):863-6
31. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 1997;56(3):168-72
32. Harrison CN, Campbell PJ, Buck G. et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353(1):33-45
33. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350(2):114-24
34. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med 2005;353(1):85-6
35. Van Genderen PJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997;97(1):179-84
36. Michiels JJ, Koudstaal PJ, Mulder AH, Van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43(6):1107-10
37. Griesshammer M, Bangerter M, Van Vliet HH, Michiels JJ. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 1997;23(4):371-7
38. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110(3):577-83
39. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med 2000;133(11):925-6
40. Ferster A, Sariban E, Meuleman N. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 2003;123(2):368-9
41. Petrides PE. Anagrelide: what was new in 2004 and 2005? Semin Thromb Hemost 2006;32(4 Part 2):399-408
42. Tefferi A, Silverstein MN, Petitt RM, et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 1997;23(4):379-83
43. Dingli D, Tefferi A. Anagrelide: an update on its mechanisms of action and therapeutic potential. Expert Rev Anticancer Ther 2004;4(4):533-41
44. Jurgens DJ, Moreno-Aspitia A, Tefferi A. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia. Haematologica 2004;89(11):1394-5
45. Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 2006;106(11):2397-405
46. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 1996;22(Suppl 1):135-42
47. Silver RT. Interferon alfa: effects of long-term treatment for polycythemia vera. Semin Hematol 1997;34(1):40-50
48. Mazzucconi MG, Francesconi M, Chistolini A, et al. Pipobroman therapy of essential thrombocythemia. Scand J Haematol 1986;37(4):306-9
49. Passamonti F, Malabarba L, Orlandi E, et al. Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. Br J Haematol 2002;116(4):855-61
50. Van De Pette JE, Prochazka AV, Pearson TC, et al. Primary thrombocythaemia treated with busulphan. Br J Haematol 1986;62(2):229-37
51. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia 2007;21(8):1658-68